|Articles|August 1, 1998

August 1998
Volume 4
Issue 8

Correspondence regarding, "A Cost-Effectiveness Clinical Decision Analysis Model for Schizophrenia"

Author(s)Penny Mohr, Peter Neumann, Karl Claxton

Download PDF: Correspondence regarding, "A Cost-Effectiveness Clinical Decision Analysis Model for Schizophrenia"

Articles in this issue

almost 28 years ago

Article

The Impact of Reimbursement Changes for Intracoronary Stents on Providers and Medicare

almost 28 years ago

Article

Formulary Limitations and the Elderly: Results from the Managed Care Outcomes Project

almost 28 years ago

Article

The Cost of Inpatient Endometriosis Treatment: An Analysis Based on the Healthcare Cost and Utilization Project Nationwide Inpatient Sample

almost 28 years ago

Article

Identification and Assessment of High-Risk Seniors

almost 28 years ago

Article

Outpatient Antidepressant Utilization in a Dutch Sick Fund

almost 28 years ago

Article

Inborn Errors of Metabolism: Medical and Administrative "Orphans"

almost 28 years ago

Article

Treatment Options for Prostate Cancer: Part 2 -- Early and Late Stage and Hormone Refractory Disease

almost 28 years ago

Article

Generic Drug Product Equivalence: Current Status

almost 28 years ago

Article

The Clinical Value of Commonly Used Spinal Fluid Diagnostic Studies in the Evaluation of Patients with Suspected Multiple Sclerosis

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Correspondence regarding, "A Cost-Effectiveness Clinical Decision Analysis Model for Schizophrenia"

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

Jeff Hunnicutt to Bring Community Oncology Roots to New Role as Navista COO

Diagnosing Alzheimer's Disease Agitation: Triggers, Care Specialties, and the Role of Primary Care

Contributor: State Leaders Need Real-World Evidence to Integrate Social Care at Scale

Nipocalimab Improves gMG Outcomes Across East Asian Subgroup

New MINT Trial Analysis Favors Liberal Transfusion After MI